
Akers Biosciences, Inc. EBITDA 2011-2025 | AKER
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Akers Biosciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -12.3 M | -3.76 M | -8.38 M | -4.88 M | -4.46 M | -6.82 M | -2.95 M | -1.55 M | -2.19 M | -3.33 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.55 M | -12.3 M | -5.06 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLife Solutions
BLFS
|
-1.97 M | $ 24.56 | 0.7 % | $ 1.13 B | ||
|
Baxter International
BAX
|
1.01 B | $ 19.52 | 1.93 % | $ 9.96 B | ||
|
Becton, Dickinson and Company
BDX
|
5.04 B | $ 200.48 | -0.23 % | $ 57.7 B | ||
|
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | ||
|
Ekso Bionics Holdings
EKSO
|
-8.85 M | $ 4.68 | 0.21 % | $ 94.4 M | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
3.37 M | $ 0.71 | -4.45 % | $ 30.1 M | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
ICU Medical
ICUI
|
262 M | $ 148.28 | -0.1 % | $ 3.62 B | ||
|
iRhythm Technologies
IRTC
|
-94.8 M | $ 170.21 | 0.82 % | $ 5.31 B | ||
|
Alcon
ALC
|
580 M | $ 79.15 | 0.43 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
-28.8 M | $ 41.07 | -3.09 % | $ 1.93 B | ||
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
electroCore
ECOR
|
-18.3 M | $ 4.85 | 2.11 % | $ 26.7 K | ||
|
Repro Med Systems
KRMD
|
-9.4 M | $ 5.8 | 0.35 % | $ 264 M | ||
|
AngioDynamics
ANGO
|
-14.2 M | $ 13.42 | 2.13 % | $ 548 M | ||
|
The Cooper Companies
COO
|
1.06 B | $ 81.36 | -0.88 % | $ 16.2 B | ||
|
LeMaitre Vascular
LMAT
|
61.9 M | $ 83.04 | -1.14 % | $ 1.86 B | ||
|
Glaukos Corporation
GKOS
|
-95 M | $ 111.73 | 2.6 % | $ 5.41 B | ||
|
Masimo Corporation
MASI
|
-164 M | $ 137.35 | -0.72 % | $ 7.32 B | ||
|
Haemonetics Corporation
HAE
|
337 M | $ 80.24 | -3.89 % | $ 4.04 B | ||
|
InfuSystem Holdings
INFU
|
15 M | $ 9.22 | -0.27 % | $ 190 M | ||
|
Merit Medical Systems
MMSI
|
258 M | $ 86.49 | -0.24 % | $ 5.04 B | ||
|
Isoray
ISR
|
-88.6 M | - | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
2.79 B | $ 559.7 | 3.2 % | $ 199 B | ||
|
OraSure Technologies
OSUR
|
-17.4 M | $ 2.49 | - | $ 185 M | ||
|
Microbot Medical
MBOT
|
-9.75 M | $ 2.23 | -7.65 % | $ 22.7 M | ||
|
Milestone Scientific
MLSS
|
-6.72 M | $ 0.36 | -7.4 % | $ 28.7 M | ||
|
Nephros
NEPH
|
-1.38 M | $ 4.98 | -0.8 % | $ 51.7 M | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
ResMed
RMD
|
1.16 B | $ 251.67 | -0.27 % | $ 36.8 B | ||
|
Envista Holdings Corporation
NVST
|
-915 M | $ 22.07 | 0.46 % | $ 3.8 B | ||
|
Pro-Dex
PDEX
|
11.9 M | $ 44.0 | 1.43 % | $ 145 M | ||
|
STAAR Surgical Company
STAA
|
-5.72 M | $ 23.49 | -2.65 % | $ 1.15 B | ||
|
STERIS plc
STE
|
1.34 B | $ 253.98 | 0.82 % | $ 25 B | ||
|
Stereotaxis
STXS
|
-21.2 M | $ 2.35 | -1.05 % | $ 190 M | ||
|
Pulse Biosciences
PLSE
|
-43 M | $ 14.04 | -1.4 % | $ 674 M | ||
|
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 32.4 M | ||
|
Repligen Corporation
RGEN
|
116 M | $ 160.09 | 1.72 % | $ 8.92 M | ||
|
Utah Medical Products
UTMD
|
17.4 M | $ 57.54 | -0.96 % | $ 209 M | ||
|
DENTSPLY SIRONA
XRAY
|
-530 M | $ 11.43 | -1.21 % | $ 2.32 B | ||
|
Retractable Technologies
RVP
|
-13.5 M | $ 0.84 | 1.99 % | $ 25.1 M | ||
|
Teleflex Incorporated
TFX
|
426 M | $ 126.88 | 0.17 % | $ 5.94 B | ||
|
West Pharmaceutical Services
WST
|
725 M | $ 271.82 | 1.6 % | $ 19.8 B |